These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 6903495)

  • 41. In-vitro activity of penicillin G plus sulbactam in comparison with other beta-lactamase inhibitor combinations and oxacillin against staphylococci.
    Jansen B; Perdreau-Remington F; Pulverer G
    Zentralbl Bakteriol; 1996 Jul; 284(2-3):297-301. PubMed ID: 8837390
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Penicillinase activity of staphylococci resistant to polysynthetic penicillins].
    Shneerson AN; Rezvan SP
    Antibiotiki; 1967 Mar; 12(3):200-6. PubMed ID: 5187119
    [No Abstract]   [Full Text] [Related]  

  • 43. The combined oxacillin resistance and coagulase (CORC) test for rapid identification and prediction of oxacillin resistance in Staphylococcus species directly from blood culture.
    Carey BE; Nicol L
    J Clin Pathol; 2008 Jul; 61(7):866-8. PubMed ID: 18381379
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Experiences with the typing of coagulase-negative staphylococci and micrococci.
    de Saxe MJ; Notley CM
    Zentralbl Bakteriol Orig A; 1978 Jul; 241(1):46-59. PubMed ID: 696068
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Antistaphylococcal activity in vitro of penicillin G, propicillin, oxacillin and dicloxacillin].
    Ciaffi G; Del Piano M; Monacelli E
    Antibiotica; 1966 Sep; 4(3):201-9. PubMed ID: 4966376
    [No Abstract]   [Full Text] [Related]  

  • 46. [On the oxacillin resistance of pathogenic Staphylococci. I. Nature of resistance against oxacillin in Staphylococcus pyogenes aureus].
    Kayser FH; Wiemer U
    Z Hyg Infektionskr; 1965; 150(4):308-16. PubMed ID: 5175787
    [No Abstract]   [Full Text] [Related]  

  • 47. [Fosfomycin, a new antibiotic: in vitro activity compared with mezlocillin, cefuroxime and gentamicin].
    Lindenschmidt EG; Schassan HH
    Immun Infekt; 1980; 8(4):121-6. PubMed ID: 6453080
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antibiotic susceptibility of oxacillin-resistant staphylococci.
    Klastersky J
    Antimicrob Agents Chemother; 1972 May; 1(5):441-6. PubMed ID: 4494488
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Staphylococcus lugdunensis: antimicrobial susceptibility and optimal treatment options.
    Taha L; Stegger M; Söderquist B
    Eur J Clin Microbiol Infect Dis; 2019 Aug; 38(8):1449-1455. PubMed ID: 31144243
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Activity in vitro of some semisynthetic penicillins produced in antibiotic factories of Jassy, on pathogenic staphylococci. II. Action of cloxacillin and dicloxacillin].
    Teodorovici G; Zvorişteanu V; Groll M; Ivan A; Năstase A; Gottschling M
    Rev Med Chir Soc Med Nat Iasi; 1972; 16(3):691-4. PubMed ID: 5080562
    [No Abstract]   [Full Text] [Related]  

  • 51. [Oxacillin-resistant staphylococci in routine diagnosis].
    Gatermann S; Laufs R
    Immun Infekt; 1987 May; 15(3):110-1. PubMed ID: 3649334
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Factors influencing the growth of staphylococci localized in cellophane sacs in vivo. I. Comparative diffusion and antibacterial effect of three penicillin analogues.
    Abu-Nassar H; Yow EM; Williams T; Dolan M
    Chemotherapia (Basel); 1964-1965; 9(6):309-20. PubMed ID: 5322140
    [No Abstract]   [Full Text] [Related]  

  • 53. [Has the rate of resistant staphylococci increased recently? (author's transl)].
    Spitzy KH; Rotter M
    Infection; 1979; 7 Suppl 2():S220-4. PubMed ID: 255137
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Establishing MIC breakpoints for coagulase-negative Staphylococci to oxacillin.
    Andrews JM; Boswell FJ; Wise R
    J Antimicrob Chemother; 2000 Feb; 45(2):259-61. PubMed ID: 10660515
    [No Abstract]   [Full Text] [Related]  

  • 55. [Comparative study of the activity of various antibiotics on pathogenic Staphylococcus aureus].
    Janbon M; Bertrand A; Pourquier M
    Chemotherapy; 1965-1966; 10(4):229-44. PubMed ID: 5874621
    [No Abstract]   [Full Text] [Related]  

  • 56. Bacteriological assessment of clindamycin, a new lincomycin derivative.
    Chadwick P
    J Med Microbiol; 1971 Nov; 4(4):529-34. PubMed ID: 5002688
    [No Abstract]   [Full Text] [Related]  

  • 57. Comment on: Cerebrospinal fluid impairs antimicrobial activity of fosfomycin in vitro.
    Beer R; Helbok R; Lackner P; Broessner G; Schmutzhard E; Pfausler B
    J Antimicrob Chemother; 2010 Sep; 65(9):2058-9; author reply 2059-60. PubMed ID: 20542906
    [No Abstract]   [Full Text] [Related]  

  • 58. Evaluation of fosfomycin combined with vancomycin against vancomycin-resistant coagulase negative staphylococci.
    Ibrahim YM; Abu El-Wafa WM
    J Chemother; 2020 Dec; 32(8):411-419. PubMed ID: 32372690
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Synergism and antagonism between antibiotics; effect of associated penicillin with chloramphenicol on penicillin resistant and penicillin sensitive Staphylococci].
    SORICE F; ORTONA L
    G Batteriol Immunol; 1953; 45(7-8):316-31. PubMed ID: 13095752
    [No Abstract]   [Full Text] [Related]  

  • 60. Clostridium perfringens type A. Comparison of in vitro and in vivo activity of twelve antimicrobial drugs.
    Traub WH
    Chemotherapy; 1986; 32(1):59-67. PubMed ID: 2868848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.